Iylon Precision Oncology shared a post in LinkedIn:
“Precision Oncology with Radioimmunotherapy for Peritoneal Carcinomatosis
In this paper ‘Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation’, Dr. Nicole Aguirre and the team summarize the recent advances of Precision Oncology with Radioimmunotherapy for peritoneal carcinomatosis.
Peritoneal carcinomatosis is a condition in which cancer cells spread throughout the lining of the abdomen, often arising from cancers of the stomach, colon, ovaries, or other abdominal organs. The treatment, known as radioimmunotherapy, uses different types of radioactive particles to destroy cancer cells more precisely.
Early research in laboratory and animal models has shown encouraging results, suggesting that this targeted approach could improve treatment outcomes. Ongoing research aims to translate these findings into effective clinical therapies, helping bring more personalized and precise treatment options to patients with peritoneal carcinomatosis.
The video illustrates the role of Precision Oncology with Radioimmunotherapy for peritoneal carcinomatosis․
At Iylon Precision Oncology, we harness genetic insights to provide personalized, evidence-based recommendations, helping guide the right medicine, for the right patient, at the right dose, at the right time, and aimed at the right target.”
Title: Radioimmunotherapy for peritoneal carcinomatosis: Preclinical proof of concept to clinical translation
Authors: Nicole Aguirre, Darren Veach, Andrea Cercek, Sarah Cheal, Steven Larson, Garrett Nash, Nai-Kong Cheung
Read the Full Article.
Other articles featuring Iylon Precision Oncology on OncoDaily.